FDA approves new antibacterial drug Avycaz
The U.S. Food and Drug Administration today approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 25, 2015 Category: American Health Source Type: news
Actavis And Valeant Announce FDA Approval For Metronidazole
Actavis and Valeant Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) has approved Metronidazole 1.3% Vaginal Gel. The approved New Drug Application (NDA) is for an antibiotic to treat bacterial vaginosis (BV). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 7, 2014 Category: Pharmaceuticals Source Type: news
US FDA approves Actavis-Valeant's NDA for Metronidazole 1.3% vaginal gel
The US Food and Drug Administration (FDA) has approved Actavis-Valeant's new drug application (NDA) for Metronidazole 1.3% vaginal gel, an antibiotic for treatment of bacterial vaginosis (BV). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2014 Category: Pharmaceuticals Source Type: news
Unichem Laboratories gets USFDA nod for Metronidazole tablets
The drug is an anti-infective agent used to treat a variety of bacterial and protozoal infections. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 23, 2014 Category: Pharmaceuticals Source Type: news
Fecal Transplant Cost Effective for Recurrent C DifficileFecal Transplant Cost Effective for Recurrent C Difficile
Fecal transplant is more cost effective than vancomycin, metronidazole, or fidaxomicin for recurring Clostridium difficile infection, researchers report. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Multidrug-Resistant Bacteroides fragilisMultidrug-Resistant Bacteroides fragilis
One of the leading pathogens isolated in the setting of intra-abdominal infections, B. fragilis strains are virtually always susceptible to metronidazole, carbapenems, and beta-lactam antibiotics -- except when they're not . . . Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 1, 2013 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
PARSIPPANY, N.J., and MONTREAL, May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Actavis, Inc. (ACT), and Valeant Pharmaceuticals International, Inc. (VRX) (VRX) today announced that Actavis Specialty Brands (the "Company") has acquired ... Biopharmaceuticals, AcquisitionsValeant Pharmaceuticals, Actavis, Metronidazole (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 1, 2013 Category: Pharmaceuticals Source Type: news
Vancomycin or Metronidazole in Patients With PSCVancomycin or Metronidazole in Patients With PSC
How well do antibacterial agents, such as vancomycin or metronidazole, work in the treatment of primary sclerosing cholangitis? This new study takes a look. Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 19, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
